No drug or therapy has been officially approved to treat Marburg virus disease. Treatment today still rests on aggressive supportive care, keeping the patient alive long enough for the immune system to clear the virus. That said, the pipeline of experimental options has grown considerably in recent years, with monoclonal antibodies, antiviral drugs, RNA-based therapies, and combination regimens all showing strong results in animal models, and some now being tested in humans during outbreaks. The gap between laboratory promise and bedside reality remains the central challenge.
Why Marburg Is So Hard to Treat
Marburg virus attacks the body on multiple fronts simultaneously. It targets immune cells early, depleting lymphocytes and triggering a flood of inflammatory signaling molecules that can spiral into what researchers call a cytokine storm, a runaway inflammatory response that damages blood vessels and organs. At the same time, the virus suppresses the adaptive immune system, impairing the body’s ability to produce effective antibodies on its own.1PubMed Central. Immunogenicity, Pathogenesis, and Host’s Immuno-Responses to Marburg Virus Infection The result is a disease that overwhelms both the patient’s defenses and, historically, the medical infrastructure available in the regions where outbreaks occur.
Case fatality rates in past outbreaks have ranged from roughly 24% to nearly 90%, depending on the strain and the quality of medical care. That enormous range hints at something important: how you treat the supportive-care side of the equation matters a great deal, even without a specific antiviral drug.
Supportive Care as a Treatment in Its Own Right
For decades, “supportive care” for Marburg meant basic fluid replacement and hoping for the best. That has changed. During the 2024 Rwanda outbreak, the third largest Marburg outbreak on record, medical teams provided intensive-care-level support including mechanical ventilation, blood product transfusions, advanced imaging, and careful electrolyte management guided by laboratory monitoring. Two critically ill patients who would almost certainly have died under older standards of care recovered.2The Lancet Infectious Diseases. Marburg Virus Treatment: What Are the Options? The Rwanda experience demonstrated that optimized supportive care is not just a stopgap; it actively changes survival odds.
This matters for how you think about the treatment landscape. Even as experimental drugs move through development, the biggest immediate gains in survival may come from making sure patients in future outbreaks have access to well-staffed intensive care units with reliable supplies of blood products and electrolytes. That is easier said than done in rural sub-Saharan Africa, where most outbreaks occur, but the evidence from Rwanda shows the payoff is real.
Monoclonal Antibodies
The most advanced experimental treatment category involves monoclonal antibodies, lab-made versions of the antibodies the immune system would ideally produce on its own. The leading candidate is a human monoclonal antibody called MR191-N. In rhesus macaques infected with Marburg virus, MR191-N provided up to 100% survival when treatment started as late as five days after infection.3PubMed Central. Therapeutic treatment of Marburg and Ravn virus infection in nonhuman primates with a human monoclonal antibody Five days post-infection is well into the symptomatic phase in these animal models, which makes the result especially encouraging.
MR191 works by blocking the virus’s ability to enter cells. To infect a cell, Marburg virus needs to bind to a receptor called NPC1 inside cellular compartments. MR191 physically plugs the binding site on the virus’s surface protein, mimicking part of the receptor itself and outcompeting it. The antibody essentially tricks the virus into grabbing the wrong thing.4PubMed Central. The Marburgvirus-neutralizing human monoclonal antibody MR191 targets a conserved site to block virus receptor binding
A closely related antibody, MR186-YTE, has also shown complete protection in macaques when given five days post-infection, with treated animals showing only mild symptoms like fever and decreased appetite before recovering fully.5Nature Communications. Combination therapy protects macaques against advanced Marburg virus disease The “YTE” modification in this antibody’s name refers to an engineering change that extends its half-life in the body, potentially allowing a single dose to remain effective longer.
Remdesivir and Other Antiviral Drugs
Remdesivir, the antiviral drug that gained wide recognition during the COVID-19 pandemic, was originally developed with filoviruses like Ebola and Marburg in mind. In cynomolgus macaques infected with Marburg virus, animals given a loading dose of remdesivir starting five days after infection had an 83% survival rate, compared to zero survival in untreated controls.6PubMed Central. Combination therapy with remdesivir and monoclonal antibodies protects nonhuman primates against advanced Sudan virus disease Animals receiving a lower dose without the loading regimen still had 50% survival, and all treated animals showed improvements in liver and kidney function markers and blood clotting compared to controls.7The Journal of Infectious Diseases. Remdesivir (GS-5734) Is Efficacious in Cynomolgus Macaques Infected With Marburg Virus
Remdesivir works differently from monoclonal antibodies. Rather than blocking the virus from entering cells, it interferes with the virus’s ability to copy its genetic material once inside, acting as a faulty building block that jams the replication machinery. Preclinical data suggest it works best when administered early, ideally within 24 to 48 hours of exposure, though the macaque studies show benefit even at five days post-infection.8PubMed Central. Post-exposure prevention in Marburg virus outbreaks: potential role of remdesivir in emergency response A significant practical limitation is that remdesivir must be given intravenously, which complicates use in field settings with limited medical infrastructure.
Favipiravir, an antiviral that can be taken orally, offers a potential alternative. When given intravenously in one study, five of six macaques infected with Marburg virus survived, an 83% success rate.9PubMed. Efficacy of favipiravir (T-705) in nonhuman primates infected with Ebola virus or Marburg virus The oral formulation could be a game-changer for outbreak response in remote areas, though achieving adequate drug levels through oral dosing has been a challenge in filovirus research. Another small-molecule candidate, galidesivir, a nucleoside analog, has also shown preclinical promise in suppressing Marburg virus replication, adding to the toolkit of drugs that might eventually be tested in humans.
RNA Interference Therapies
A fundamentally different approach uses small interfering RNA (siRNA), short synthetic RNA molecules designed to silence specific genes the virus needs to replicate. For Marburg, the most effective target has been the gene encoding the virus’s nucleoprotein, a structural protein essential for viral replication. In guinea pig studies, siRNA targeting Marburg nucleoprotein mRNA and delivered via lipid nanoparticles provided 100% protection against two Marburg strains and 60% against the related Ravn virus. Combining two different siRNA sequences pushed Ravn virus protection to 100% as well.10PubMed Central. Protection Against Lethal Marburg Virus Infection Mediated by Lipid Encapsulated Small Interfering RNA
The results scaled up impressively. In a study using rhesus monkeys challenged with a lethal dose of the most dangerous Marburg strain (Angola), all 16 animals treated with the siRNA therapy survived, even when treatment started as late as three days after infection. Every untreated control animal died within seven to nine days.11PubMed Central. Marburg virus infection in nonhuman primates: Therapeutic treatment by lipid-encapsulated siRNA Those results, 100% survival against a virus with a near-100% fatality rate in the untreated group, are among the most striking in filovirus therapeutic research.
The main hurdle with siRNA therapies is delivery. Lipid nanoparticles need to be administered intravenously and require cold-chain storage. The technology has matured significantly since the COVID-19 mRNA vaccines demonstrated that lipid nanoparticle delivery can be manufactured at scale, but field deployment during a rural African outbreak remains a logistical challenge that has not yet been solved.
The Case for Combination Therapy
Perhaps the most practically important finding in recent preclinical work is that combining a monoclonal antibody with remdesivir extends the treatment window beyond what either drug achieves alone. In rhesus macaques, both MR186-YTE and remdesivir individually produced strong protection when started five days after infection. But when treatment was delayed to six days, neither drug alone saved any animals. Combining the two at that same six-day time point rescued 80% of the animals.5Nature Communications. Combination therapy protects macaques against advanced Marburg virus disease
Researchers believe the combination works because the two drugs hit the virus from different directions and distribute differently through the body. Remdesivir reduces the amount of new virus being produced inside already-infected cells, while the antibody intercepts free virus particles and prevents them from infecting new cells. Because the two drugs have very different physical properties, they likely reach different tissues and body compartments, closing off more escape routes for the virus than either drug alone.12Nature Communications. Combination therapy protects macaques against advanced Marburg virus disease – Section: Discussion This has major practical implications: patients in real outbreaks often do not seek medical care until they are already severely ill, so therapies that work at later stages of disease are exactly what the field needs.
Post-Exposure Prophylaxis
A related but distinct question is what to do for someone who has been exposed to Marburg virus but is not yet sick, say a healthcare worker with a needlestick injury or a family member who cared for a patient before the diagnosis was known. The leading post-exposure strategy involves a recombinant vaccine based on vesicular stomatitis virus (rVSV), the same platform used in the licensed Ebola vaccine Ervebo. In macaque studies, this vaccine provided complete protection when given within 20 to 30 minutes of exposure, protected five of six animals when given at 24 hours, and still saved two of six at 48 hours.13PubMed Central. Postexposure treatment of Marburg virus infection
The declining effectiveness over time highlights an obvious constraint: you need to identify the exposure quickly and have the vaccine on hand. During the 2024 Rwanda outbreak, experimental vaccines were deployed for contacts of confirmed cases, though published data on outcomes from that real-world use are still pending. The window for post-exposure prophylaxis is tight, and the logistics of getting a temperature-sensitive biological product to exposed individuals within hours in a chaotic outbreak setting remain daunting.
The Strain Problem
One complication that does not always get enough attention is that Marburg virus is not a single entity. The genus includes Marburg virus (MARV) and Ravn virus (RAVV), which are genetically distinct enough that a treatment effective against one may not fully cover the other. This matters because both viruses cause clinically identical disease and circulate in overlapping regions.
Recent work has identified a new group of monoclonal antibodies that can neutralize both MARV and RAVV. Five of these antibodies target a conserved site spanning the fusion loop and receptor-binding domain of the virus’s surface protein, a region shared between the two viruses. Other antibodies in the same discovery effort specifically neutralized MARV but failed against RAVV, because they bind a region of the protein that differs between the two.14npj Viruses. Discovery of potent cross-neutralizing antibodies against Marburg and Ravn viruses with therapeutic potential Developing treatments that cover both viruses is essential, since clinicians in an outbreak cannot always distinguish which virus a patient has before treatment needs to begin.
Preventive Vaccines and How They Fit In
While vaccines are not treatments in the traditional sense, they are part of the broader response toolkit and worth understanding. The most advanced preventive vaccine candidate uses a chimpanzee adenovirus vector (cAd3-Marburg). In a first-in-human phase 1 trial, a single vaccination produced glycoprotein-specific antibodies in 95% of participants within four weeks. At 48 weeks, about 70% of participants still had detectable antibody responses, and the safety profile was comparable to similar adenovirus-vectored vaccines already in use.15The Lancet. Safety and immunogenicity of a chimpanzee adenovirus type 3-vectored Marburg virus vaccine: a first-in-human, phase 1, open-label, dose-escalation trial
No Marburg vaccine is yet licensed for general use. The challenge with Marburg, compared to diseases like measles or COVID-19, is that outbreaks are sporadic and relatively small, making traditional large-scale efficacy trials nearly impossible to run. Licensure of medical countermeasures for filoviruses may ultimately require demonstration of efficacy in nonhuman primate models rather than conventional human trials.16PubMed Central. Considerations in the Use of Nonhuman Primate Models of Ebola Virus and Marburg Virus Infection This regulatory pathway, known as the Animal Rule in the United States, allows approval based on well-designed animal studies when human efficacy trials are not ethical or feasible.
The Gap Between Animal Data and Human Reality
Almost everything we know about Marburg therapeutics comes from macaque studies. These are considered the gold standard for filovirus research because macaques develop disease that closely mimics the human version, with similar timelines, organ damage, and immune responses. But animal data do not always translate perfectly. Drug doses that work in a small primate may not achieve the same tissue concentrations in a human. Timing that seems precise in a controlled laboratory exposure becomes fuzzy in the real world, where patients may not even know when they were infected.
The 2024 Rwanda outbreak offered a rare opportunity to use experimental treatments in actual patients under relatively controlled conditions, and published accounts describe pathogen-specific treatments being administered alongside intensive supportive care.17PubMed. Safe delivery of intensive care for Marburg virus disease in Rwanda Full data from those treatments are still being analyzed. Each outbreak that allows even limited human treatment data moves the field incrementally closer to understanding what works in people, but the sporadic and unpredictable nature of Marburg outbreaks means this process is painfully slow.
Viral Persistence After Recovery
Even patients who survive Marburg virus disease may face ongoing medical concerns. Research in nonhuman primate survivors has shown that the virus can persist in immune-privileged sites, particularly the testes, long after it has been cleared from the bloodstream.18PubMed. Persistent Marburg Virus Infection in the Testes of Nonhuman Primate Survivors This mirrors findings with Ebola virus, where sexual transmission from survivors has been documented months after recovery.
The persistence of virus in these protected body compartments raises questions about whether treatments used during the acute phase also need to clear these reservoirs. Most monoclonal antibodies and antiviral drugs penetrate immune-privileged sites poorly. Researchers have suggested that approaches targeting the local immunosuppression in these tissues, essentially helping the immune system reach places it normally cannot, may be needed as a follow-up to acute treatment. This is an area with more questions than answers, but it means that even a drug that cures the acute disease might not end the public health risk posed by a recovered patient.
What Convalescent Plasma Cannot Do
Given the success of monoclonal antibodies, a natural question is whether blood plasma from recovered patients could serve as a simpler, low-tech alternative. Convalescent plasma, in which antibodies from survivors are transfused into sick patients, has a long history in infectious disease and was widely used during the early COVID-19 pandemic and during the West African Ebola outbreak. For Marburg specifically, the evidence is thin. The immune suppression that Marburg virus causes means that survivors may not produce particularly potent or broadly neutralizing antibodies, and the volume of plasma needed from the small number of survivors in any given outbreak creates obvious supply constraints. Lab-manufactured monoclonal antibodies can be produced in standardized concentrations and selected for potency, which is why the field has largely moved toward engineered antibodies rather than relying on whatever nature provides in a survivor’s blood.
Practical Barriers to Deploying Any of These Treatments
The science is further ahead than the logistics. Remdesivir requires intravenous infusion over multiple days. Monoclonal antibodies need cold-chain storage and trained personnel for administration. siRNA therapies require lipid nanoparticle formulation and intravenous delivery. Even the post-exposure vaccine needs refrigeration and rapid deployment within hours. Marburg outbreaks tend to occur in areas with limited healthcare infrastructure, unpaved roads, and sometimes active conflict. Stockpiling experimental treatments that may never be used, because outbreaks are unpredictable and sometimes years apart, creates difficult decisions about where to invest scarce health budgets.
The oral antiviral route, exemplified by favipiravir, could sidestep some of these challenges. A pill that patients can take at home or at a local clinic would transform outbreak response in a way that even the most effective injectable therapy cannot. But oral antivirals for filoviruses are still in relatively early stages of development, and achieving the drug exposure levels needed to suppress a virus this aggressive through a pill remains a pharmacological challenge.
Temperature stability is another often-overlooked factor. Biologic therapies like monoclonal antibodies typically require refrigeration between 2 and 8 degrees Celsius. In equatorial Africa, where daytime temperatures routinely exceed 30°C and electricity can be unreliable, maintaining a cold chain from manufacturing to patient bedside is a non-trivial undertaking that adds cost and complexity to every link in the supply chain. Engineered modifications like the YTE change mentioned earlier, which extends antibody half-life, also tend to improve stability, but no current Marburg therapeutic has been designed specifically for tropical field deployment.